SCHEMBL6921487

SCHEMBL6921487

CCN(CC)CCOc1cccc2c1c1cccc(F)c1n2Cc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.43
ESR2 Q92731 2/20 0.43
PLA2G2A P14555 1/20 0.41
HTR1B P28222 2/20 0.38
HTR1D P28221 1/20 0.38
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
DRD1 P21728 1/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
POLB P06746 1/20 0.37
KDM4E B2RXH2 2/20 0.36
MCL1 Q07820 1/20 0.36
ALDH1A1 P00352 1/20 0.36
BIRC5 O15392 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6924339 0.94 DRD2 (0.46) ESR1ESR2PLA2G2AHTR1BHTR1D
SCHEMBL6926705 0.91 TP53 (0.43) ESR1ESR2PLA2G2AHTR1BHTR1D
SCHEMBL6927305 0.91 ESR1 (0.42) ESR1ESR2PLA2G2AHTR1BHTR1D
SCHEMBL6920875 0.85 MEN1 (0.43) ESR1ESR2PLA2G2AHTR1BHTR1D
SCHEMBL6924574 0.82 ESR1 (0.41) ESR1ESR2PLA2G2ADRD2DRD3
SCHEMBL6924126 0.82 ESR1 (0.43) ESR1ESR2PLA2G2ADRD2DRD3
SCHEMBL6925172 0.82 TP53 (0.47) ESR1ESR2PLA2G2AHTR1BHTR1D
SCHEMBL6924596 0.82 DRD2 (0.49) ESR1ESR2PLA2G2AHTR1BHTR1D
SCHEMBL6927241 0.80 DRD2 (0.51) ESR1ESR2PLA2G2AHTR1BHTR1D
SCHEMBL7505287 0.80 ESR1 (0.44) ESR1ESR2PLA2G2ADRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US claimed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP claimed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO claimed
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US disclosed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP disclosed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO disclosed